Orchid Pharma Ltd (ORCHPHARMA) Stock Analysis: Valuation, Latest Results, Financial Ratios & DeciZen Rating

BSE: 524372 | NSE: ORCHPHARMA | Pharmaceuticals & Drugs | Small Cap

Orchid Pharma Share Price

865.15 0.00 0.00%
as on 05-Dec'25 15:23

Orchid Pharma Ltd (ORCHPHARMA) Stock Analysis: Valuation, Latest Results, Financial Ratios & DeciZen Rating

BSE: 524372 | NSE: ORCHPHARMA | Pharmaceuticals & Drugs | Small Cap

DeciZen - make an informed investing decision on Orchid Pharma

Based on:

Overall Rating
Login to view analysis. Bole Toh

1. Quality


Login to view analysis.

2. Valuation


Login to view analysis.

3. Price Trend


Login to view analysis.

Orchid Pharma stock performance -

Key Ratios
mw4me loader
P/E Ratio (SA):
60.79
Market Cap:
4,388 Cr.
52-wk low:
603.8
52-wk high:
1,998

Is Orchid Pharma Ltd an attractive stock to invest in?


Login to view analysis.

10 Year X-Ray of Orchid Pharma: Login to view analysis.

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Orchid Pharma Ltd has performed well in some of the past ten years indicating its past ten year financial track record is somewhat good

Value Creation

Value Creation Index Colour Code Guide

Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25TTM
ROCE % 0.1%-6.4%-3.4%-3.8%-4.3%-3.5%-1.9%8.8%9%8.5%-
Value Creation
Index
-1.0NANA-1.3-1.3-1.3-1.1-0.4-0.3-0.4-

Growth Parameters

Growth Parameters Colour Code Guide

Sales 879755644584481451557666819922821
Sales YoY Gr.--14.1%-14.7%-9.4%-17.6%-6.3%23.6%19.6%23.1%12.5%-
Adj EPS -27.9-41.1-38.43.7-18.8-24.2-14.35.817.820.214.2
YoY Gr.-NANANA-603.2%NANANA207.6%13.3%-
BVPS (₹) 19.2-29.7-75.8-84.9195.5166.9166.1179.3240.2261.1265
Adj Net
Profit
-248-366-34233.2-76.6-98.9-58.423.690.210272
Cash Flow from Ops. 2113185.615.280.424.489.613.413127.5-
Debt/CF from Ops. 15.29.8573.5212.7718.6324.816.3-

CAGR

CAGR Colour Code Guide

9 Years 5 Years 3 Years 1 Years
Sales 0.5%13.9%18.3%12.5%
Adj EPS NANANA13.3%
BVPS33.6%6%16.3%8.7%
Share Price 32.3% 75.2% 29.4% -49.1%

Key Financial Parameters

Performance Ratio Colour Code Guide

Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25TTM
Return on
Equity %
-81.3789.572.9-4.6-357.8-13.4-8.63.49.385.4
Op. Profit
Mgn %
19.812.26.510.6613.110.512.713.6129
Net Profit
Mgn %
-28.2-48.4-535.7-15.9-21.9-10.53.51111.18.8
Debt to
Equity
18.8-11.8-4.8-4.30.70.70.40.50.10.10.1
Working Cap
Days
691737735766616318271265249275154
Cash Conv.
Cycle
8564251782151142140122127113

Recent Performance Summary

Login to view analysis.
Login to view analysis.

Latest Financials - Orchid Pharma Ltd.

Standalone Consolidated
TTM EPS (₹) 14.2 10.3
TTM Sales (₹ Cr.) 821 821
BVPS (₹.) 265 251.2
Reserves (₹ Cr.) 1,293 1,223
P/BV 3.27 3.44
PE 60.79 83.97
From the Market
52 Week Low / High (₹) 603.80 / 1998.00
All Time Low / High (₹) 3.04 / 2680.00
Market Cap (₹ Cr.) 4,388
Equity (₹ Cr.) 50.7
Face Value (₹) 10
Industry PE 40.7

Management X-Ray of Orchid Pharma:

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged *0.000.000.000.000.000.000.000.000.000.00
* Pledged shares as % of Promoter's holding (%)

Valuation of Orchid Pharma - Standalone Basis

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

mw4me loader

Event Update

Login/Register to view analysis.

Analyst's Notes

data not found
No data found!

Key Ratios of Orchid Pharma

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Profit And Loss

(All Figures are in Crores.)
PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25
Sales879755644584481451557666819922
Operating Expenses 705663622590470392498582709811
Manufacturing Costs14713911410398688697103116
Material Costs419367331278200229314385484544
Employee Cost 83758279726460657086
Other Costs 5781951291003038355265
Operating Profit 1749222-611595984111111
Operating Profit Margin (%) 19.8%12.2%3.4%-1.1%2.4%13.0%10.5%12.7%13.5%12.0%
Other Income 251920172469193145
Interest 294331310765233331715
Depreciation 14313913313011810987553334
Exceptional Items -53-1730250003900
Profit Before Tax -292-532-401-101-88-96-535592106
Tax -17-48-4600000-30
Profit After Tax -274-484-355-101-88-96-535595106
PAT Margin (%) -31.2%-64.0%-55.2%-17.3%-18.4%-21.3%-9.5%8.3%11.6%11.6%
Adjusted EPS (₹)-30.8-54.4-39.9-11.4-21.7-23.5-12.913.518.721.0
Dividend Payout Ratio (%)0%0%0%0%0%0%0%0%0%0%

Balance Sheet

(All Figures are in Crores.)
PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25

Equity and Liabilities

Shareholders Fund 171-264-674-7557986816787321,2181,324
Share Capital 89898989414141415151
Reserves 82-353-763-8447576416376911,1681,273
Minority Interest0000000000
Debt3,0112,7562,5882,120504430231290134174
Long Term Debt2,3782,1571,8941,425504427208149120132
Short Term Debt63460069469503231411443
Trade Payables3534043272706069121129179170
Others Liabilities 4275659701,358884464722028
Total Liabilities 3,9633,4613,2112,9931,4501,2241,0941,2231,5521,697

Fixed Assets

Gross Block2,8932,8931,4251,4251,2471,1761,1761,2201,2971,328
Accumulated Depreciation1,3531,492133263389506593647681715
Net Fixed Assets 1,5401,4021,2911,161858670584573616613
CWIP 28028827227826710462444
Investments 125125125001549506969
Inventories210197185167141151173229264326
Trade Receivables37524614514166132160212189242
Cash Equivalents 31325630132417219422257164
Others Assets 1,11894689292118723011591131238
Total Assets 3,9633,4613,2112,9931,4501,2241,0941,2231,5521,697

Cash Flow

(All Figures are in Crores.)
PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25
Cash Flow From Operating Activity 2113186158024901313127
PBT -292-445-401-101-150-117-55492106
Adjustment 49657645023517516438544224
Changes in Working Capital 7188-36-11545-2758-95-3-102
Tax Paid 00-7-4105-2-01-1
Cash Flow From Investing Activity -1-9-284516767113-27-316-37
Capex -1-9-6-7-4-0145-26-55-69
Net Investments 0-0-343714767-33-1-272109
Others 0012152410112-77
Cash Flow From Financing Activity -287-36633-0-250-165-2173116725
Net Proceeds from Shares 18000400003920
Net Proceeds from Borrowing -27-128-10-1,044-125-205-110-2200
Interest Paid -265-219-4-0-0-40-32-32-5-3
Dividend Paid 0000000000
Others -13-19390754020173029
Net Cash Flow -76-571160-3-73-1418-1816

Finance Ratio

PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25
Ratios
ROE (%)-89.85N/AN/AN/A-413.02-12.96-7.767.849.728.38
ROCE (%)0.08N/AN/AN/A-4.28-3.5-1.868.778.968.52
Asset Turnover Ratio0.220.210.190.190.220.340.480.570.590.57
PAT to CFO Conversion(x)N/AN/AN/AN/AN/AN/AN/A0.241.380.25
Working Capital Days
Receivable Days137148110897980961028985
Inventory Days9397108110117118106110110117
Payable Days282376403392301103110119116117

Orchid Pharma Ltd Stock News

Orchid Pharma Ltd FAQs

The current trading price of Orchid Pharma on 05-Dec-2025 15:23 is ₹865.1.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 04-Dec-2025 the market cap of Orchid Pharma stood at ₹4,388.
The latest P/E ratio of Orchid Pharma as of 04-Dec-2025 is 60.79.
The latest P/B ratio of Orchid Pharma as of 04-Dec-2025 is 3.27.
The 52-week high of Orchid Pharma is ₹1,998 and the 52-week low is ₹603.8.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Orchid Pharma is ₹821.3 ( Cr.) .

About Orchid Pharma Ltd

Orchid Chemicals & Pharmaceuticals (Orchid) is pharmaceutical company engaged in development and manufacture of active pharmaceutical ingredients (APIs) and finished dosage forms. It is also engaged in research of new drugs. The company was Incorporated in the year 1992 as a 100% export-oriented unit (EOU).

Orchid has employee strength of over 3700 people, out of which over 600 are scientists, technologists and other professionals.

The drug major has two manufacturing unit for APIs located at Alathur and Aurangabad and three facilities for fosage forms at Irungattukottai and Alathur. Besides this it two research and development centres located at Sholinganallur and Irungattukottai, Chennai.

It has formed an alliance with North China Pharmaceutical Corporation (NCPC), which is the largest pharmaceutical group in China to manufacture and market pharmaceuticals products.

The company has formed distribution and marketing alliance with various global pharmaceutical corporations including Apotex, Actavis, Hospira and Dava, among others.

Orchid owns two subsidiaries, whose core focus are on drug discovery and development namely Orchid Research Laboratories in Chennai and Bexel Pharmaceuticals in the US. Besides this, it also has subsidiary such as Orgenus Pharma Inc (USA), Orchid Pharmaceuticals Inc (USA), Ogna Farma (South America) and Orchid Europe.

During March 2010, Orchid Chemicals & Pharmaceuticals had completed the transaction for sale and transfer of Orchid's generic injectable finished dosage forms Pharmaceuticals business to Hospira Healthcare India, a subsidiary of Hospira, Inc.

In January 2011, Orchid Chemicals & Pharmaceuticals had signed a memorandum of understanding with Great Lakes Institute of Management for setting up a centre of excellence in technopreneurship at Great Lakes campus near Chennai. The MoU was signed in the presence of APJ Abdul Kalam, former President of India, during the inauguration of Great Lakes' B-school festival, L’Attitude 13° 05’.

In April 2011, Orchid Chemicals had attained an out-of-court settlement with world's largest drug maker Pfizer Inc to sell a low-cost version of the American firm's patented anti-depressant drug, Effexor XR, (extended release) in the US market this fiscal.

In 2012
 - Orchid Pharma exit its Chinese JV with NCPC
 - Orchid Pharma enters into agreement to transfer its Penicillin & Penem API business & its API facilities in Aurangabad to Hospira for approximately US$ 200 million

In 2013
- Orchid enters into strategic partnership with Allecra Therapeutics for development of novel antibiotics

Products

Active Pharmaceutical Ingredients- Orchid develops a wide range of APIs in category of oral cephalosporins, betalactams, special nutraceuticals, etc.

Formulations- Under this the company is engaged in developing formulation in various segment such anti-infectives, anti-oxidants, oral anti-diabetics, etc.

Awards


Orchid was awarded as the Top Indian Public Limited Company in Patent at the 5th National Intellectual Property Award 2013, organized by CII in partnership with the Department of Industrial Policy & Promotion and Indian Intellectual Property Office, Government of India.
Orchid received EXIM Achievement Award 2012 for its meritorious export performance by The Tamil Chamber of Commerce, Chennai.

Orchid was conferred with the Export Excellence Award 2010-11 by MEPZ – Special Economic Zone, Government of India.

Orchid received EXIM Achievement Award 2011 for its meritorious export performance under the category Air Exports by The Tamil Chamber of Commerce, Chennai.

Orchid was conferred the Gold Patent Award for the year 2010-11 in recognition of its commendable contribution to R&D in Drug Discovery Sector by the Pharmaceutical Export Promotion Council. The award was presented by Shri. N. Kiran Kumar Reddy, Hon’ble Chief Minister of Andhra Pradesh.
Orchid was awarded IGCW – 2011 Green Innovation Award for the outstanding research in the field of Green Chemistry & Engineering in 2011.

Orchid was conferred the Shrishti Good Green Governance (G3) Award in 2011. The award was presented by Mr. Salman Khurshid, Minister of Water Resources & Minority Affairs, Government of India.

In 2010, for ""Outstanding Achievement in Environment Management in the Chemical sector"", Orchid was conferred with the Silver Award by Greentech Foundation.

Orchid was awarded the ""Siemens Ecovatives-IBN Live Award 2010"" in recognition of our outstanding initiatives in Energy Management (Low Energy and Natural Resource Conservation).

In 2010, Orchid’s Alathur API facility received the Bureau of Energy Efficiency (BEE) Certificate of Merit on Energy Efficiency by the Ministry of Power, Government of India.

Orchid’s endeavour in the area of energy conservation was recognised with the “Excellent Energy Efficient Unit” in the 9th Energy Efficiency Summit 2010 organised by the CII (Confederation of Indian Industries). This award was recently presented by Mr.Ajay Mathur, Director General of Bureau of Energy Efficiency, Ministry of Power, and Government of India.

Orchid’s Aurangabad facility received the Dr.R J Rathi Award for Environment Pollution & Control in industries in Maharashtra for the year 2010 (constituted by Maharashtra Chamber of Commerce Industries & Agriculture, Pune)

Orchid's Alathur facility was awarded Certificate of Appreciation by the National Safety Council of India (Safety Awards - 2011) in recognition of its appreciable achievement in Occupational Safety & Health during the assessment period of three years from 2008-10.

In 2011, Orchid received the ""Green Tech Gold Safety Award"" by Greentech Foundation. The award was presented by Dr RK Srivastav, Director General of Health Services, Ministry of Health & Family Welfare, Gov of India  and Mr Kamaleshwar Sharan, President, Greentech Foundation.

Orchid’s Alathur facility received the Greentech Safety Award 2010 (Silver award) in pharmaceutical sector for outstanding achievement in Safety Management given by Greentech Foundation.

Orchid was awarded the ""Certificate of Merit Award"" for 2010 by the CII for Excellence in Environment, Health and Safety.

Orchid Research Laboratories (the discovery subsidiary of Orchid) won the Partner of Choice Award for Contract Research - Collaborative Drug Discovery by Frost & Sullivan in April 2007.

The company also bagged Gold Award for Excellence and Business Prestige was awarded at the Quality Summit 2003, New York.

 

To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×